tallózása szerző szerint "Grusch M"

A találatok rendezése: Rendezés: Találatok:

  • Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. 
    Mathieu V; Pirker C; Schmidt WM; Spiegl-Kreinecker S; Lotsch D; Heffeter P; Hegedűs, Balázs; Grusch M; Kiss R; Berger W (2012)
    Melanoma is a devastating skin cancer characterized by distinct biological subtypes. Besides frequent mutations in growth- and survival-promoting genes like BRAF and NRAS, melanomas additionally harbor complex non-random ...
  • Apelin promotes lymphangiogenesis and lymph node metastasis 
    Berta, Judit; Hoda MA; Laszlo, Viktoria; Rozsas A; Garay, Tamás; Torok S; Grusch M; Berger W; Paku, Sándor; Rényi-Vámos, Ferenc István; Masri B; Tóvári, József; Groger M; Klepetko W; Hegedűs, Balázs; Döme, Balázs (2014)
    Whereas the role of the G-protein-coupled APJ receptor and its ligand, apelin, in angiogenesis has been well documented, the ability of the apelin/APJ system to induce lymphangiogenesis and lymphatic metastasis has been ...
  • Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma 
    Klikovits T; Stockhammer P; Laszlo V; Dong Y; Hoda MA; Ghanim B; Opitz I; Frauenfelder T; Nguyen-Kim TDL; Weder W; Berger W; Grusch M; Aigner C; Klepetko W; Döme, Balázs; Rényi-Vámos, Ferenc István; Oehler R; Hegedűs, Balázs (2017)
    Only limited information is available on the role of complement activation in malignant pleural mesothelioma (MPM). Thus, we investigated the circulating and tissue levels of the complement component 4d (C4d) in MPM. Plasma ...
  • Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. 
    Ghanim B; Hoda MA; Klikovits T; Winter MP; Alimohammadi A; Grusch M; Döme Balázs; Arns B; Schenk P; Jakopovic M; Samarzija M; Brcic L; Filipits M; Laszlo Viktoria; Klepetko W; Berger W; Hegedüs Balázs (2014)
    Background:To investigate the clinical utility of pretreatment plasma fibrinogen levels in malignant pleural mesothelioma (MPM) patients.Methods:A retrospective multicenter study was performed in histologically proven MPM ...
  • Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis 
    Heinzle C; Gsur A; Hunjadi M; Erdem Z; Gauglhofer C; Stattner S; Karner J; Klimpfinger M; Wrba F; Réti, Andrea; Hegedűs, Balázs; Baierl A; Grasl-Kraupp B; Holzmann K; Grusch M; Berger W; Marian B (2012)
    A gly(388)arg polymorphism (rs351855) in the transmembrane domain of the fibroblast growth factor receptor (FGFR4) is associated with increased risk, staging, and metastasis in several different types of cancer. To ...
  • Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma. 
    Lohinai, Zoltán; Hoda MA; Fábián, Katalin; Ostoros, Gyula; Rásó, Erzsébet; Barbai, Tamás; Tímár, József; Kovalszky, Ilona; Cserepes, Tamás Mihály; Laszlo, Viktoria; Grusch M; Berger W; Klepetko W; Moldvay, Judit; Döme, Balázs; Hegedűs, Balázs (2015)
    INTRODUCTION:: While classic sensitizing mutations of epidermal growth factor receptor (EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma, there are rare EGFR mutations ...
  • Epigenetic down-regulation of integrin alpha7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma 
    Laszlo V; Hoda MA; Garay, Tamás; Pirker C; Ghanim B; Klikovits T; Dong YW; Rózsás, Anita; Kenessey, István; Szirtes, Ildikó; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zochbauer-Muller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Döme, Balázs; Hegedűs, Balázs (2015)
    Malignant pleural mesothelioma (MPM) is a devastating malignancy characterized by invasive growth and rapid recurrence. The identification and inhibition of molecular components leading to this migratory and invasive ...
  • Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma 
    Rozsas A; Berta, Judit; Rojko L; Horvath LZ; Keszthelyi M; Kenessey, István; Laszlo, Viktoria; Berger W; Grusch M; Hoda MA; Torok S; Klepetko W; Rényi-Vámos, Ferenc István; Hegedűs, Balázs; Döme, Balázs; Tóvári, József (2013)
    Recombinant human erythropoietins (rHuEPOs) are used to treat cancer-related anemia. Recent preclinical studies and clinical trials, however, have raised concerns about the potential tumor-promoting effects of these drugs. ...
  • Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy 
    Schelch K; Hoda MA; Klikovits T; Munzker J; Ghanim B; Wagner C; Garay, Tamás; Laszlo, Viktoria; Setinek U; Döme, Balázs; Filipits M; Pirker C; Heffeter P; Selzer E; Tóvári, József; Török, Szilvia; Kenessey, István; Holzmann K; Grasl-Kraupp B; Marian B; Klepetko W; Berger W; Hegedűs, Balázs; Grusch M (2014)
    RATIONALE: Malignant pleural mesothelioma is an aggressive malignancy characterized by frequent resistance to chemo- and radiotherapy, poor outcome, and limited therapeutic options. Fibroblast growth factors (FGFs) and ...
  • Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis 
    Kirschner MB; Pulford E; Hoda MA; Rózsás, Anita; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; Laszlo V; Klikovits T; Vallely MP; Grusch M; Hegedűs, Balázs; Döme, Balázs; Klepetko W; van Zandwijk N; Klebe S; Reid G (2015)
    BACKGROUND: Fibulin-3 (FBLN3) was recently presented as a promising novel biomarker for malignant pleural mesothelioma (MPM), warranting independent validation studies. METHODS: ELISA was used to measure cellular and ...
  • Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study 
    Ghanim B; Klikovits T; Hoda MA; Lang, György; Szirtes, Ildikó; Setinek U; Rozsas A; Rényi-Vámos, Ferenc István; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz, Tibor; Döme, Balázs; Hegedűs, Balázs (2015)
    BACKGROUND: Estimating the prognosis in malignant pleural mesothelioma (MPM) remains challenging. Thus, the prognostic relevance of Ki67 was studied in MPM. METHODS: Ki67 index was determined in a test cohort of 187 cases ...
  • Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells 
    Molnár, Eszter; Rittler D; Baranyi, Marcell; Grusch M; Berger W; Döme, Balázs; Tóvári, József; Aigner C; Tímár, József; Garay, Tamás; Hegedűs, Balázs (2018)
    BACKGROUND: Currently, there are no available targeted therapy options for non-V600 BRAF mutated tumors. The aim of this study was to investigate the effects of RAF and MEK concurrent inhibition on tumor growth, migration, ...
  • Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations 
    Garay, Tamás; Molnár, Eszter; Juhasz E; Laszlo V; Barbai, Tamás; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár, József; Hegedűs, Balázs (2015)
    BRAF and NRAS are the two most frequent oncogenic driver mutations in melanoma and are pivotal components of both the EGF and FGF signaling network. Accordingly, we investigated the effect of BRAF and NRAS oncogenic mutation ...
  • Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells 
    Hoda MA,; Munzker J,; Ghanim B,; Schelch K,; Klikovits T,; Laszlo, Viktoria; Sahin E; Bedeir A; Lackner A; Döme, Balázs; Setinek U; Filipits M; Eisenbauer M; Kenessey, István; Török Szilvia; Garay, Tamás; Hegedűs, Balázs; Catania A; Taghavi S; Klepetko W; Berger W; Grusch M (2012)
    Background:Activins control the growth of several tumour types including thoracic malignancies. In the present study, we investigated their expression and function in malignant pleural mesothelioma (MPM).Methods:The ...